Other diseases
Moyamoya disease
烟雾病Moyamoya
A progressive narrowing and blockage of the main arteries inside the skull, with a network of small vessels forming at the base of the brain. It occurs in children and adults; studies in China find two age peaks, the larger one in adults.
Definition adapted from MeSH (US National Library of Medicine), World Neurosurg 2019, Stroke Vasc Neurol 2021
Not in the first or second national rare-disease catalogue (2018, 2023; checked 10 November 2026).
- hospitals in mainland China
- 47
- cities
- 26
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 29% of the world's English-language research papers on moyamoya disease, 2021–2025 (22% in 2016–2020), and 49% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
47 hospitals in 26 cities
Order: papers led on moyamoya disease, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on moyamoya disease, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens moyamoya disease in that city. 16 more cities are in the menu below.
- 60 papers led
- 46 papers led
- 17 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 31
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 71 papers led6 hospitals
- 46 papers led1 hospital
- 24 papers led4 hospitals
- 17 papers led3 hospitals
- 13 papers led1 hospital
- 12 papers led1 hospital
- 11 papers led2 hospitals
- 10 papers led1 hospital
- 9 papers led3 hospitals
- 9 papers led3 hospitals
- 7 papers led4 hospitals
- 7 papers led1 hospital
- 7 papers led2 hospitals
- 7 papers led2 hospitals
- 6 papers led1 hospital
- 6 papers led2 hospitals
- 5 papers led2 hospitals
- 5 papers led3 hospitals
- 5 papers led1 hospital
- 4 papers led1 hospital
- 4 papers led2 hospitals
- 4 papers led3 hospitals
- 4 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led3 hospitals
- 3 papers led3 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
open trials on moyamoya disease in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 15 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- Recruiting5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07781579
Age not stated (registered criteria)
Led by Beijing HospitalBeijing
- RecruitingEfficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07889531
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
- RecruitingTreatment of Moyamoya Disease With iPSC-derived Exosomes
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07065409
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingStudy on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06817434
Age 18 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingStudy on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06832839
Age 18 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingFamily-Based Moyamoya Susceptibility and Early Detection
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07517354
Age not stated (registered criteria)
Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing
- RecruitingFunctional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
- Phase
- Not given
- Started
- 2023-10
- Registry
- NCT06041659
Age 18 years to 65 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingLong-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
- Phase
- Not given
- Started
- 2022-05
- Registry
- NCT05332756
Age 2 years to 60 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingThe Evolution and Prognosis of Moyamoya Disease
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT05619068
Age 10 years to 60 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRegistry of Multicenter Brain-Heart Comorbidity in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT05961748
Age 18 years to Not stated (registered criteria)
Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou
- Not yet recruitingEvaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07762547
Age 18 years to 70 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Enrolling by invitationFufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT07875335
Age 18 years to 60 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationClinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT07894640
Age 18 years to 60 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationClinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT07906652
Age 18 years to 60 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
No national diagnosis and treatment guideline for this disease was found on the National Health Commission website (searched 10 November 2026).
Where these numbers come from
Papers
356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.